Seeking Alpha author Sharon de Stefano jumps to Oramed's (ORMP +6.7%) defense after the tongue lashing the company received from Adam Feuerstein over Phase IIa trial results sent its shares into a tailspin.
Feuerstein focused on a chart which showed what appeared to be high rates of adverse events.
However, de Stefano accuses Feuerstein of not distinguishing between the levels of those events, and implies that he doesn't know what he's talking about. "Clinical data is often difficult for physicians to interpret, much less laymen, and jumping to inaccurate conclusions is not uncommon," de Stefano writes.
The side effects in the Oramed study were dizziness, nausea, constipation and headaches, which are "of little concern to the FDA in a diabetes study," says de Stefano.